-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Phase 2 CAPTIVATE study evaluated the efficacy of irutinib in the first-line treatment of chronic lymphocytic leukemia in two cohorts (randomized treatment termination cohort and fixed course cohort guided by tiny residual lesions
In both cohorts, all patients received three courses of ilutinib (420 mg/day) followed by 12 courses of ilutinib + venetok
In the total study population (n=323), a decrease in baseline data was observed since the introduction of irutinib: the proportion of patients with lymph node diameter ≥5 cm decreased from 31% to 4%, the proportion of patients with an absolute lymphocyte count ≥ 25× 109/L decreased from 76% to 65%, the proportion of patients with high TLS risk in the tumor burden category decreased from 23% to 2%, and patients with inpatient indications (high TLS risk or medium TLS risk and creatinine clearance<80 mL/80 mL/CYC min) patient rate decreased from 43% to 18%.
In summary, three courses of irutinib introduction therapy prior to initiating venetok provide effective tumor reduction, reduce TLS risk classes, and reduce hospitalizations requiring intensive TLS surveillance
Original source:
Paul M.
